进展期卵巢癌腹腔温热化疗的Meta分析

发布时间：2018-06-29 15:18

本文选题：卵巢肿瘤 + 腹腔温热化疗　；参考：《实用医学杂志》2015年22期

【摘要】：目的:系统评价进展期卵巢癌腹腔温热化疗(hyperthermic intraperitoneal chemotherapy,HIPC)的疗效及安全性。方法:计算机检索Cochrane Library、Pub Med、EMBASE、CBM和CNKI,并辅以其他检索。收集所有比较中晚期卵巢癌术中或术后应用HIPC与术后常规静脉或腹腔化疗的随机对照试验(randomized controlled trial,RCT)。使用Review Manager 5.1进行Meta分析。结果 :共纳入7个RCT研究。HIPC组的总生存率明显高于对照组,差异有统计学意义。2个RCT研究对术后复发率的Meta分析结果显示,HIPC组明显低于对照组,差异有统计学意义。两组化疗后毒副反应无统计学差异。结论:与常规静脉或腹腔化疗相比,进展期卵巢癌术中或术后应用HIPC可提高患者总生存率、降低术后复发率,安全性可以接受。
[Abstract]:Objective: to evaluate the efficacy and safety of (hyperthermic intraperitoneal hyperthermia chemotherapy (hyperthermic intraperitoneal) in advanced ovarian cancer. Methods: the Cochrane Library Pub Medus EMBASEN CBM and CNKI were searched by computer and supplemented by other searches. To collect all randomized controlled trials (randomized controlled Trial RCT) that compare the intraoperative or postoperative use of HIPC with routine intravenous or intraperitoneal chemotherapy in patients with advanced ovarian cancer. Meta analysis using Review Manager 5.1. Results: the overall survival rate in the 7 RCT studies. HIPC group was significantly higher than that in the control group, and the Meta-analysis of postoperative recurrence rate in two RCT studies showed that the overall survival rate of HIPC group was significantly lower than that of the control group, and the difference was statistically significant. There was no significant difference in side effects between the two groups after chemotherapy. Conclusion: compared with conventional intravenous or intraperitoneal chemotherapy, HIPC during or after operation of advanced ovarian cancer can improve the overall survival rate, reduce the recurrence rate, and the safety is acceptable.
【作者单位】：中国医科大学附属第一医院妇科;中国人民解放军202医院妇产科;辽宁省大连市妇产医院妇科;
【基金】：辽宁省自然科学基金资助项目(编号:2014021021)
【分类号】：R737.31

【参考文献】